Podcasts about mrd

In this episode, Solomon Moshkevich, president of clinical diagnostics at Natera, discusses how molecular data, MRD testing, and AI-driven tools are transforming clinical decision making across oncology, prenatal care, and chronic kidney disease. He shares insights on evidence generation, system integration, and the opportunities ahead for more personalized, cost-effective care.This episode is sponsored by Natera.

Das Time Magazine kürt die "Architects of AI" zur Person of the Year 2025. OpenAI kontert Googles Gemini-Erfolg mit GPT 5.2 und übertrifft in vielen Benchmarks wieder die Konkurrenz. Disney investiert eine Milliarde Dollar in OpenAI und bringt 200 Charaktere auf Sora. OpenAI holt sich eine Salesforce-Veteranin als Chief Revenue Officer. SpaceX peilt beim IPO jetzt 1,5 Billionen Dollar an. Meta gibt Open Source auf und baut ein geschlossenes Modell namens "Avocado". DeepSeek nutzt trotz Sanktionen Nvidia Blackwell Chips. Das Pentagon stattet Mitarbeiter mit Google Gemini aus. Die USA fordern bei Einreise künftig fünf Jahre Social Media History. Berliner Zahnärzte verzocken eine Milliarde Euro Rentengelder in Venture Deals. Palantir-Gründer fordert öffentliches Erhängen von Straftätern. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Intro (00:01:23) Time Person of the Year: The Architects of AI (00:09:34) OpenAI GPT 5.2: Neues Flagship-Modell schlägt Benchmarks (00:15:58) OpenAI wird zum Attention-Grabber wie Social Media (00:20:00) OpenAI holt Slack-CEO als Chief Revenue Officer (00:23:19) Disney investiert $1 Mrd. in OpenAI für Sora-Charaktere (00:32:21) OpenAI plant Adult Content für 2026 (00:38:23) SpaceX IPO: Bewertung jetzt bei $1,5 Billionen (00:41:31) Margin Debt verdoppelt: Bubble-Indikator? (00:48:11) Pentagon nutzt Google Gemini (genai.mil) (00:55:04) Venture Capital Fundraising kollabiert auf $60 Mrd. (00:56:04) Meta gibt Open Source auf: Neues Modell "Avocado" (00:56:55) DeepSeek nutzt Nvidia Blackwell Chips trotz Sanktionen (00:58:30) Oracle Earnings (01:02:04) USA fordern 5 Jahre Social Media History bei Einreise (01:05:39) Berliner Zahnärzte verzocken 1 Mrd. Euro Rentengelder (01:08:56) Palantir Gründer fordert Erhängen (01:14:36) El Salvador kauft Grok für Schulbildung (01:15:30) KI-Hacker besser als 9 von 10 Menschen (01:17:00) Russische Schiffe und Drohnen über Deutschland Shownotes KI-Architekten: Personen des Jahres 2025 - time.com GPT5.2- wired Einführung von GPT-5.2 - openai.com Denise Dresser: Von Slack-CEO zur Chief Revenue Officer bei OpenAI - wired.com Disney und Sora einigen sich - openai.com Disney Google - variety ChatGPTs Erwachsenenmodus kommt 2026 - gizmodo.com SpaceX plant Börsengang 2026 mit über 30 Milliarden Dollar Bewertung - bloomberg.com Zeitpunkt der platzenden Aktienmarktblase bestimmen - linkedin.com Pentagon wählt Google AI-Plattform für Millionen von Mitarbeitern - bloomberg.com Pip Tweet VC- x.com Metas Wandel: Vom Open-Source-Projekt zum profitablen KI-Modell - bloomberg.com DeepSeek verwendet verbotene Nvidia-Chips für nächstes Modell. - theinformation.com Oracle Q2-Gewinnbericht 2026 - wsj.com Grenzkontrollen: Einfluss von Social Media auf Touristenvisa - nytimes.com Zahnärzte - tagesspiegel US Marine enthüllt "ShipOS" mit Palantir zur Beschleunigung des Schiffbaus - axios.com Joe Lonsdale von Palantir äußert sich zu öffentlichen Hinrichtungen - independent.co.uk Elon Musk: Grok-Initiative in El Salvador - theguardian.com KI-Hacker kommen gefährlich nah daran, Menschen zu übertreffen - wsj.com Iron Man - instagram.com Drohnen - digitaldigging.org Google Deepmind - ft.com

Der DAX startet stark, kippt aber mit schwacher Wall Street und endet bei 24.186 Punkten mit -0,5 %. Zuvor standen 24.475 Punkte auf der Kurstafel, der EuroStoxx50 schloss bei 5.720 Punkten mit -0,6 %. In den USA drückte eine Broadcom Warnung vor geringeren Margen bei KI-Systemen die Tech Stimmung, Siemens Energy verlor 4,3 % als KI-Zulieferer. Silber lief weiter heiß und markierte mit 64,23 USD je Unze ein Rekordhoch. Adidas führte den DAX mit rund 2 % an, Merck fiel nach JP Morgan Kursziel 150 Euro ans Ende. Fraport plant für 2025 wieder 1,00 Euro Dividende je Aktie, warnt aber wegen 140 Mio. Euro zusätzlicher Abschreibungen und 90 Mio. Euro höherer Zinsen vor schwächerem Ergebnis 2026. T Mobile US will im kommenden Jahr Aktien für bis zu 14,6 Mrd. USD zurückkaufen. VW baut Cupra Born weiter in Zwickau, ID.3 bleibt länger. Henkel bekommt Gegenwind: Die FTC klagt gegen den Kauf von Liquid Nails für 725 Mio. USD. Lufthansa sprang bis auf 8,64 Euro und lag zeitweise 6,9 % im Plus nach Kepler Hochstufung auf "Buy".

The future of cancer care is shifting toward earlier detection, continuous monitoring, and truly personalized treatment powered by high-quality genomic insights. In this episode, Ajay Gannerkote, President of Integrated DNA Technologies, explains how rapid advances in genomics are transforming cancer diagnosis, precision medicine, and personalized care. He describes how IDT evaluates emerging technologies by combining custom manufacturing, high-quality reagents, and deep scientific partnerships to deliver clinically meaningful insights. Ajay highlights how NGS, MRD, and multi-cancer detection are expected to accelerate over the next 3–5 years, enabling far earlier diagnosis and more precise monitoring. He also underscores the power of collaboration, shares a rare pediatric success story, and reflects on leadership principles centered on trust, innovation, and an “obligation to dissent.” Tune in and learn how the next wave of genomic innovation is bringing precision medicine within reach for patients everywhere! Resources Connect with and follow Ajay Gannerkote on LinkedIn. Follow Integrated DNA Technologies on LinkedIn and visit their website!

Thu, 11 Dec 2025 16:31:00 +0000 https://jungeanleger.podigee.io/2829-kapitalmarkt-stimme-at-daily-voice-martina-geisler-ey-sieht-fur-osterreich-eine-solide-ipo-pipeline-bei-small-mid-caps-sowie-spin-offs 3591bbfdf170785e19aad819c7febd0a kapitalmarkt-stimme.at daily voice auf audio-cd.at: Laut EY IPO Barometer legte die Zahl der IPOs in 2025 weltweit um zwei Prozent auf 1.259 (Vorjahr: 1.240) zu. Das Emissionsvolumen steigerte sich um 32 Prozent auf rund 163,3 Mrd. US-Dollar. Im vierten Quartal 2025 gingen weltweit 347 Unternehmen an die Börse – ein Rückgang von fünf Prozent im Vergleich zum Vorjahresquartal (366). Dagegen stieg das Emissionsvolumen um 15 Prozent auf 51,7 Mrd. US-Dollar. Der weltweit größte Börsengang des Jahres war die chinesische Contemporary Amperex Technology Co. Ltd mit rund 5,3 Mrd. US-Dollar Emissionserlösen. Der größte europäische IPO fand im vierten Quartal statt: Das Schweizer Unternehmen Verisure erzielte fast 4,2 Mrd. US-Dollar. In Deutschland war die Ottobock SE & Co. KGaA mit einem Emissionsvolumen von rund 865 Mio. US-Dollar der größte Börsengang – zugleich auch mit rund 5 Mrd. US-Dollar Marktkapitalisierung am IPO-Tag der wertvollste deutsche Neuzugang. Martina Geisler, Partner und Leiterin IPO bei EY Österreich ist für das kommende Jahr zuversichtlich: „Für das kommende Jahr sehen wir vorsichtigen Optimismus – vorausgesetzt, das makroökonomische Umfeld entwickelt sich stabil. In Europa gibt es eine umfangreiche Pipeline mit vielen Unternehmen, die auf ein passendes Marktfenster warten. Für den deutschen Markt rechnen wir 2026 mit einem Potenzial von bis zu zehn IPOs aus unterschiedlichen Segmenten – vom Mittelstand über Großunternehmen bis hin zu Private-Equity-Exits und Wachstumsunternehmen. Auch in Österreich ist eine solide Pipeline erkennbar, insbesondere im Mid- und Small-Cap-Segment sowie bei potenziellen Spin-offs. Wir gehen davon aus, dass 2026 – abhängig vom Marktfenster – mehrere KMU-Listings sowie selektive größere Transaktionen möglich sind.“ Unser Ziel: Kapitalmarkt is coming home. Täglich zwischen 19 und 20 Uhr. kapitalmarkt-stimme.at daily voice Playlist auf spotify: http://www.kapitalmarkt-stimme.at/spotify http://www.kapitalmarkt-stimme.at Musik: Steve Kalen: https://open.spotify.com/artist/6uemLvflstP1ZerGCdJ7YU Playlist 30x30 (min.) Finanzwissen pur: http://www.audio-cd.at/30x30 Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/apple http://www.audio-cd.at/spotify Du möchtest deine Werbung in diesem und vielen anderen Podcasts schalten? Kein Problem!Für deinen Zugang zu zielgerichteter Podcast-Werbung, klicke hier.Audiomarktplatz.de - Geschichten, die bleiben - überall und jederzeit! 2829 full no Christian Drastil Comm. (Agentur für Investor Relations und Podcasts)

Robert Engel, Head of Business Development Retail Germany bei Allianz Global Investors, mit einem flammenden Plädoyer für monatlich ausschüttende Anteilklassen ausgesuchter AGI-Fonds – was wir wie gewohnt konstruktiv kritisch hinterfragen. Welche Bedürfnisse und Lebenssituationen passen zu diesen Anlagelösungen? Was ist Marketing, was Psychologie und was Storyline? Wir diskutieren Gemeinsamkeiten und Unterschiede zu Auszahlplänen, sprechen über den Zinseszinseffekt und steuerliche Aspekte, alternative Angebote der Wettbewerber, Auszeichnungen für Innovationen und gehen zuletzt der Frage nach, warum in Asien in diese Anteilklassen bereits über 25 Mrd. Euro eingezahlt wurden.

Er ist CSU-Vorsitzender und Ministerpräsident von Bayern. Ich wollte von ihm wissen, warum er bei vielen Menschen so starke Reaktionen hervorruft, wie er ein Star auf Instagram wurde, wie man mit der AfD umgehen sollte und wie man eine Überzeugung ändert, die man lange vertreten hat. Wir sprechen über Macht und Verantwortung, frühes Aufstehen und Fotos, deren Wirkung im Internet sich nicht kontrollieren lässt, über Game of Thrones und natürlich über Bayern. WERBEPARTNER & RABATTE: https://linktr.ee/hotelmatze MEIN GAST: https://www.instagram.com/markus.soeder/ DINGE: Markus Söder - Der Schattenkanzler: Biographie (Roman Deininger / Uwe Ritzer) https://bit.ly/48LVFsy Game of Thrones https://bit.ly/3Yjay0J Spiderman Comics https://bit.ly/3MyV71O Fakten: Markus Söder und die Rettung der Bayerischen Landesbank (BayernLB) https://bit.ly/4q4Z7pw Heute schnelle Hochwasserhilfen. 2017 aber noch Hochwasshilfen abgeschafft. https://bit.ly/4pZZBNu Statistisch gesehen war Bayern zunächst am härtesten von der Pandemie getroffen, konnte aber ab April einen starken Rückgang der Totenzahlen verzeichnen https://bit.ly/3KJJEMf Investitionen Bayern in den Klimaschutz. Haushaltsvolumen des Staatsministeriums für Umweltschutz und Verbraucherschutz: 1,252 Mrd. EUR https://bit.ly/451QeVk Klimschutzinvestitionen: Bundesländer im Vergleich (2022): https://bit.ly/4pFMqRS Bruttoinlandsprodukt nach Bundesländern: https://bit.ly/44mfzZT Maximilian Frisch - Produktion Torben Becker - Redaktion Mit Vergnügen - Vermarktung und Distribution Hotel Matze live - https://eventim.de/artist/hotel-matze/ MEIN ZEUG: Mein Fragenset FAMILIE: https://beherzt.net/products/familie Mein Fragenset LIEBE: https://beherzt.net/liebe Mein erstes Fragenset: https://beherzt.net/matze Meine Spendenaktion: https://machmit.wellfair.ngo/hotel-matze-spendenaktion-2025 Mein Newsletter: https://matzehielscher.substack.com/ YouTube: https://bit.ly/2MXRILN TikTok: https://tiktok.com/@matzehielscher Instagram: https://instagram.com/matzehielscherHotel LinkedIn: https://linkedin.com/in/matzehielscher/ Mein Buch: https://bit.ly/39FtHQy

Die US-Arbeitskosten stiegen im dritten Quartal nur um 0,8 % – weniger als erwartet und der kleinste Anstieg seit 2020. Auf Jahressicht liegt der Zuwachs bei 3,5 %, ein Signal, dass der Arbeitsmarkt die Inflation derzeit kaum antreibt. Die Märkte bleiben vor der Fed-Entscheidung ruhig: S&P 500 flach, Dow +0,2 %, Nasdaq –0,3 %, bei einer 90 % Wahrscheinlichkeit für die dritte Zinssenkung in Folge. Gleichzeitig bleibt der FOMC gespalten, was der heutigen Forward Guidance besondere Bedeutung gibt. Im Markt setzt sich die Rotation fort: Der Russell 2000 erreicht neue Rekorde, da Small Caps stark von sinkenden Zinsen profitieren. Und im Innovationssektor sorgt SpaceX für Schlagzeilen – der Konzern treibt einen möglichen Mega-IPO über 30 Mrd. USD voran, was der größte Börsengang aller Zeiten wäre. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

SpaceX plant für Ende 2026 einen Börsengang bei 800 Milliarden Dollar Bewertung. Google Gemini überholt ChatGPT bei den Nutzungsminuten. Meta kauft Limitless (ehemals Rewind) für sein Wearables-Team. Netflix bietet 83 Milliarden für Warner Bros. Discovery – doch Paramount/Skydance kontert mit einem feindlichen 108-Milliarden-Angebot, unterstützt von Jared Kushner und Saudi-Geld. Die EU untersucht Google wegen der Content-Nutzung für AI-Overviews und verhängt 120 Millionen Euro Strafe gegen X. Elon Musk reagiert mit Angriffen auf die EU-Kommission. Trump erlaubt Nvidia, H200-Chips nach China zu exportieren. In Russland wurden hunderte Porsches per Hack lahmgelegt. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Intro (00:02:06) SpaceX IPO: $800 Mrd. Bewertung für Ende 2026 (00:10:11) Secondary-Markt boomt: Bubble-Indikator? (00:14:00) OpenAI-Studie: 40-60 Minuten Zeitersparnis pro Tag (00:15:40) Google Gemini überholt ChatGPT bei Nutzungsminuten (00:18:42) Google Slides: KI-Bildgenerierung mit Nano Banana (00:24:33) Meta kauft Limitless (ehemals Rewind) (00:27:54) Netflix vs. Paramount: Kampf um Warner Bros. Discovery (00:35:05) EU untersucht Google wegen AI-Mode Content-Nutzung (00:41:55) EU-Fines vs. Tech-Gewinne (00:44:21) EU-Strafe: 120 Mio. Euro gegen X wegen DSA-Verstößen (00:51:30) Elon Musks politisches Muster: Persönliche Rache? (00:58:09) Starlink profitiert von Trump-Administration (01:00:32) Trump erlaubt Nvidia H200-Chips nach China (01:06:35) Porsches in Russland per Hack lahmgelegt (01:08:19) Alex Karp: Neurodivergent Fellowship nach auffälligem Auftritt (01:15:10) Karp über "High-Testosterone Males" und Männlichkeit Shownotes SpaceX plant Börsengang 2026 nach $800 Mrd. Bewertung – theinformation.com OpenAI: KI spart Arbeitern fast eine Stunde täglich – bloomberg.com OpenAIs Vorsprung unter Druck – ft.com Meta übernimmt KI-Wearable-Unternehmen Limitless – cnbc.com Netflix – theinformation.com Google von EU wegen KI-Inhaltsnutzung untersucht – cnbc.com EU-Kommission als profitabelstes Internetunternehmen der EU 2024? – linkedin.com Elon Musk fordert Abschaffung der EU nach Geldstrafe – cnbc.com EU: Elon Musks X soll 120 Mio. € Strafe zahlen – politico.eu Elon Musk: EU vs. Musk: 120 Millionen-Strafe nur der Auftakt – handelsblatt.com Wie Starlink von Elon Musks Trump-Verbindungen profitierte – restofworld.org Trump erlaubt Nvidia H200 AI-Chip-Verkäufe nach China mit 25% US-Beteiligung – cnbc.com Russland: Hunderte Porsche-Autos springen nicht mehr an – spiegel.de USA: Trump und Warner Bros. Bieterschlacht – sueddeutsche.de Alex Karp – nypost.com Alex Karp – finance.yahoo.com Alex Karp – instagram.com

Dr. Pedro Barata and Dr. Ravin Garg discuss strategies to increase trial representation, including leveraging trial navigators and prioritizing pragmatic trial models, as featured in the ASCO Educational Book article, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care." TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast from ASCO featuring compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I am a medical oncologist at University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I am also the associate editor of the ASCO Educational Book. We know that in recent years, the oncology community has increasingly prioritized the need to modernize clinical trial eligibility, reduce patient burden, and enhance diversity in trial participation. On that note, today we will be speaking about ways to enhance access to clinical trials with Dr. Ravin Garg. He is a hematologist oncologist at Maryland Oncology Hematology and also an assistant professor of oncology at Johns Hopkins Hospital in Baltimore. Dr. Garg is also the co-author of a fantastic paper in the ASCO Educational Book titled, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care."  Dr. Garg, welcome. Thanks for being here, and congrats on your paper. Dr. Ravin Garg: Thank you for having me, Pedro. I am excited to be here. Dr. Pedro Barata: [KI1]  Your paper is a wonderful, multidisciplinary piece that actually features perspectives from the different stakeholders, right? The patient advocacy, industry, community practice, and academia about these challenges in making trials more available. This podcast is a wonderful platform. It reaches out to a lot of folks within our community. So, I will start by asking you the obvious. Why do you think it is a must read for our community, for our listeners? Dr. Ravin Garg: So Pedro, thanks again for inviting me. You do a great job with these podcasts.  So, I think first and foremost, oncologists right now are under a lot of stress, just in terms of clinical volume. There is concern for research money, and how we get the best care for our patients. So I think this article is very important because it helps bring together, as you had mentioned, the stakeholders throughout academic to community practice and everywhere in between, and try to find how, as a team with different oncologists who partake in different aspects of oncology, can come together to streamline the process to try to get our patients on trials, or certainly have them have availability of trials, just if they are interested in going on them. Being in practice, we have had several challenges that we can talk about throughout this podcast, but I think it is a very important paper because it recognizes that at the end of the day, it takes a team effort for all of us in academics, community, industry, and pharmaceuticals to really come together as a team to really help put forth the trials for our patients. Dr. Pedro Barata: So, from the perspective of a community oncologist, how do you put together, or maybe you can describe some of the challenges that you see to increase trial participation in the community? Dr. Ravin Garg: Yes, Pedro, that is a great question, and it is something that I keep on thinking about and trying to find ways to be better at it myself. But I will say some of the challenges as a community doctor that I have seen for myself and talking to other colleagues. Number one, I do think there is a lot of stress on doctors in the community in general, Pedro. Oftentimes we are tasked to see a wide smorgasbord of patients, so we may not have the luxury of being a specialist in any particular tumor subtype. Like oftentimes, we will have to see lung cancer, the next one will be breast cancer, the next one could be CML, the next one could be thrombocytopenia. And as you know better than I do, Pedro, the field in each one of these disciplines is changing so rapidly: molecular genomics, radioligand treatments, different imaging tests, MRD testing for some of our hematologic malignancies. And I think one challenge we have in community is just keeping up with the basics of Oncology 101. In the process of doing that, it can be very difficult to sometimes remember that we have very exciting trials available for our patients. So, I think a lot of it is the day in and day out of being an oncologist is so taxing at times that oftentimes a research trial is not the first thing in our head space when we see a patient. I think number two, Pedro, at least in the community, and perhaps this is with academics too, is that we are bombarded, I would say, by a lot of messaging these days. We have in-baskets to go through, labs to go through, things of that nature. And in the process of a patient visit, seeing them, doing an exam, taking a history, trying to go over the NCCN guidelines on best practice for how to manage their care, at least for me at times, it is very hard to remember, "Hey, there might be a great trial available, whether within our network or maybe partnering with an academic center." So getting through a day can be fraught with a lot of peril and just difficulties, I would say. And I would say number three, Pedro, at least as, you know, I am in a private practice where I do see a wide range of benign and malignant hematology and solid tumors, so I would not call myself a specialist. And I think the challenge with that, at least for trials, Pedro, is that when you are a specialist or perhaps you are focusing on a couple of disease subtypes, you become more of an authoritative voice in those types of tumors, and you might be more aware of the trials within your network or perhaps in proxy with an academic center that you can offer your patient. So I think when sometimes we spread ourselves too thin, it can be very hard to be a thought leader, if you will, in a particular subtype of a malignancy, let's say, and maybe not be aware of a trial that could be really well-suited for your patient. In terms of ideas that myself and colleagues have had in terms of helping mitigate against some of these, I would say, setbacks or issues in the practice for trial enrollment, some of the things we have talked about, Pedro, is, number one, is we do partner with academic centers. So we live here in Maryland. We have several really fantastic academic centers. So, you know, oftentimes, not just within our practice of Maryland Oncology Hematology, we have a lot of great trials available here too, for certain, but in addition to that, we will often times work with doctors at Georgetown, Johns Hopkins, and Maryland if they have a compelling trial that we do not have within our network. It is really of the patient's interest, Pedro, to reach out to them in a collaborative manner to see if they have a trial that might be really compelling for your patient. So I do find myself collaborating a lot with colleagues in, like talented like yourself in academics. You know, I think you do a lot of GU malignancies. So as an example, like partnering with colleagues who are GU experts and say, "Hey, we have a patient with stage IV renal cell. These are the standard options I know, but are there any trials that you might have available?" I think the other thing that has been very helpful for us is having navigators within research, Pedro. Like as an example, what has really helped the uptake of trial enrollment for our center in Annapolis is having a research navigator because often times what they can do is, a priori, Pedro, before you see the patient and you are kind of formulating a standard of care treatment plan perhaps, they might tug you on the shirt and say, "Hey, we have a great trial here through Sarah Cannon, or there might be something else out there." And being aware of that when you go into a patient's room really provides a nice arena, if you will, to go and say, "The standard of care is here, but hey, we have a trial option that might be well suited for you, maybe perhaps even better, that we can talk about, too." So having research support in the community is really a huge boon, I think, Pedro, for us to really increase our enrollment for patients onto trials. Dr. Pedro Barata: Yes, I really love that, Ravin. So, let me switch gears a bit. I would love for you to talk a little bit about patient advocacy because they do play a huge role in cancer, and they address many barriers. How do you think we should leverage the patient advocacy groups to reduce patient burden and maybe have them really leverage patient advocacies to improve representation in clinical trials? What do we think we can do more? Dr. Ravin Garg: Oh, Pedro, I think they are very critically important. As a clinical oncologist now, and I would say this is for anyone in the field of medicine, you are exactly right. I think patients are bombarded by information. There are a lot of things online, whether it be TikTok, Facebook, Google, Yahoo, and people really just have a lot of information given to them. And some of it is fact driven, and some of it is not, Pedro. And oftentimes, I do think there can be at times a mistrust with some medical personnel. I think we are in an era where we are seeing that to some degree with some attributes of medicine. And I think of it as an opportunity for education for the patient and for myself as a physician. And I think patient advocates, to your point, which was well taken, serve as a bridge to both. And what I mean is that, you know, patient advocates are wonderful. They are, I think, outstanding communicators. They almost are a neutral party, Pedro, where many patients feel that they are an independent source of information that is free of bias, if you will. They are there to provide support, emotional support, scientific support for patients so they can make an informed decision. So, in terms of our practice right now, patient advocates is something that we are evolving in that capacity, I would say, Pedro. I think now more than ever, having more people as bridges of communication with care providers along with patients is of critical importance. And I would venture a guess, and I think this has been published, where patient advocates really can help tremendously in familiarizing patients with trials and what they are all about and maybe clear up some misconceptions of what trials, what the mission of trials are. Because I do think some patients, at least I have had a few over the years, where when they hear the term trial, they almost think they are being experimented upon, when, in point of fact, they could really help advance their care. That messaging along the way for some can may be mixed up a little bit. And so I think patient advocates is a really great way to offer more information for patients with a source they find very independent and trustworthy, if you will. And it can really help expedite, and I think make a more fruitful conversation for care providers, whether academic or community, and they might be more open-minded in terms of enrolling onto a trial. Dr. Pedro Barata: Wonderful. Yes, I agree. I agree with you completely.  So let's focus a little bit now on the folks designing the studies. We usually call them the sponsors. It might be an academic sponsorship, if you will, but we can also have pharma being the sponsor of a study. The angle from an academic design, it is not necessarily the same as what happens when we have pharma. And from that angle, how do you think a more inclusive research can be promoted? Dr. Ravin Garg: Oftentimes with trials, I think keeping them simple, as simple as we can. And what I mean by that is, often times for trials, Pedro, even for care providers who are enrolling, it can be daunting when there are a lot of different things involved, particularly, let's say, for investigator sponsored, which are incredibly brilliant science, incredible, but it can be a little bit daunting for patients and even the referring physician to talk about getting translational specimens, imaging, traveling to certain centers to get scans and biopsies and even different diagnostic testing like PSMA testing for, you know, prostate cancer. And it can, I think, be very intimidating for patients in terms of what might be required of him or her to enter onto a trial. Like, "This is not what I signed up for. This is laborious. This is a full time job for me. Do I have to pay for parking to go to a city? Do I have to pay for these imaging tests? And do I have to stay in a place for my family to enroll onto a trial?" So I think keeping trials as simple as possible, but yet cull the data we need as investigators where we can really advance the care, hopefully get approval for a drug, but also learn more about the medication and how it works for our patients. So I think simplifying language for trial is very important. I know when I have gone over studies for patients, Pedro, if it is a voluminous amount of information, they can right away get very intimidated. "Like, oh my goodness, this is like a term paper for college again," you know? I am joking, but you know, keeping language simplified is very important, I think, number one. And I feel that sometimes when they are asked to do a lot of different diagnostic testing, which is very important for translational work, I 100% understand, but I do think sometimes patients can get a little bit off put, if you will, and frustrated with the whole process of doing it. The second thing for our patients, Pedro, that they have mentioned to us when we put them on trials, not just within our own site but elsewhere, is that it takes a lot of time in terms of collecting information, perhaps a washout period from their last standard of treatment prior to enrollment onto a study. Many patients, Pedro, as you know better than I do, are in maybe crisis in terms of their health and their cancer might be growing, promulgating out of control, and they worry about not being able to expeditiously start onto a treatment, onto a trial. So that can lead to a lot of frustration. And one thing that you brought up, which was outstanding for me, is the enrollment criterion for some of our patients is felt to be somewhat strict. We have had some patients who may have had a remote history of a stage I malignancy that was by all accounts in remission, you know, let's say 4 or 5 years in the past, and the risk of recurrence at this point would be incredibly low, but they may not be able to enter onto a study because of some stringent criterion put forth. And that can be a little bit frustrating. In fact, I have had one or two patients who, as an example, with kidney issues, but the GFR was about 60, like right near a cutoff that oftentimes, as you know, we use where you can get into trial or not. And you know, if they are at 58, as an example, and otherwise they are a picture of health, a great candidate for a trial that will likely advance their care, and if the entry criterion is too stringent, that might be a lost opportunity for all parties involved, all stakeholders, if you will. I do appreciate the criterion for entry onto studies cannot be too liberalized. You have to have a certain baseline, but there is a little bit of a gray area and tension, of sorts, if you will, where the patient has a comorbid illness that is a disqualifying offense, but in practicality, perhaps it shouldn't be, especially if they are motivated and there is an opportunity to really advance their care. We have run into, not often, but sometimes in the past, I should say, where patients have been very off put because we try to get them onto a study and there may have been a particular feature or attribute in their underlying care that they couldn't get onto it. So I think having a little bit more thoughtfulness, perhaps, in terms of entry criterion and practicality, if you will, I think would really help enrollment onto studies. Dr. Pedro Barata: Really well said. Is there anything else that you would like to tell our listeners before we wrap up the podcast today? Dr. Ravin Garg: I would say just macroscopically speaking, it is really an honor to be an oncologist. I think I speak for both of us. Anyone listening who is thinking about the field, it is tremendous. Just the research, the bravery of our patients, and the thoughtfulness of our scientists like Pedro and translationalists and clinical trialists is really awe inspiring. So I have really loved this field. I will say from a trial perspective, we really need to enter as many patients as we can onto trials because the science is so brilliant now, the genomic underpinnings of the tumor, we are making great strides as a team of clinicians and scientists, translationalists. So the more that we can get people onto trials and get approved drugs, it is going to help them out in the end. So I think it is such an important time for all of us to come together as a community, find the best way to help our patients out. And clinical trials have to be at the forefront of how we can continue to advance care for our patients. Dr. Pedro Barata: Yeah, no Ravin, I really agree with you. We really need to increase access to clinical studies, and actually your paper is a great step in that direction by raising awareness, bringing up solutions, and again, collaboration, collaboration, collaboration is really a multidisciplinary effort to accomplish that.  Thank you so much for sharing your fantastic thoughts and insights with us. Dr. Ravin Garg: Thank you, Pedro. I am- you do a wonderful job with these podcasts. I am really honored to meet you and to be part of this. Dr. Pedro Barata: And thank you to our listeners for your time today. I encourage you to check out Dr. Garg's article in the 2025 ASCO Educational Book. We will post a link to the paper in our show notes. And please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ravin Garg Follow ASCO on social media:          @ASCO on X      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn       Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ravin Garg: Patents, Royalties, Other Intellectual Property: Creator, editor, and writer of hemeoncquestions.com  

Werbung | Exklusives Angebot für unsere Hörer: Lest das Handelsblatt 12 Monate zum halben Preis: www.handelsblatt.com/podcast50 Netflix kauft für $82,7 Mrd. den Streaming- und Filmbereich von Warner Brothers Discovery. Das traditionelle Fernsehgeschäft soll in einer separaten Transaktion ausgegliedert werden. Die Aktionäre sollen mit $23,25 in Cash und $4,50 pro Aktie in Netflix-Aktien abgefunden werden. Ein Mega-Deal, der die Branche einschneidend verändern wird. Abseits dieser Nachrichten, stehen vor allem die Ergebnisse im Fokus. Die Aktien von Ulta Beauty, Rubrik und Samsara profitieren von soliden Zahlen. DocuSign und Hewlett Packard Enterprise stehen nach den Quartalszahlen unter Druck. Wegen einer Kapitalerhöhung sehen wir bei den Aktien von SoFi vor dem Opening Abgabedruck. Um 16 Uhr MEZ wird das Dezember-Verbraucher-vertrauen der Universität von Michigan gemeldet. Der Index soll bei 52 liegen. Außerdem wird die Wall Street um die gleiche Zeit auf den September-PCE achten. Der Inflationsindikator soll im Vergleich zum Vorjahr und Vormonat um 2,8% und 0,3% gestiegen sein. Die Kernrate, die weder Nahrungsmittel noch Energie beinhaltet, soll um 2,9% und 0,2% gestiegen sein. An einer Zinssenkung in der kommenden Woche werden die Daten nichts ändern. Ein Podcast - featured by Handelsblatt. +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ +++ Hinweis zur Werbeplatzierung von Meta: https://backend.ad-alliance.de/fileadmin/Transparency_Notice/Meta_DMAJ_TTPA_Transparency_Notice_-_Ad_Alliance_approved.pdf +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html Impressum: https://www.360wallstreet.de/impressum

Ein echter Paukenschlag an der Wall Street: Netflix kauft für insgesamt $82,7 Mrd. den Streaming- und Filmbereich von Warner Brothers Discovery! Das klassische TV-Geschäft soll separat ausgegliedert werden. Für die Aktionäre gibt's 23,25 Dollar in Cash und 4,50 Dollar in Netflix-Aktien – ein Mega-Deal, der die gesamte Medien- und Entertainmentbranche verändern dürfte. Abseits dieses Deals stehen heute die Quartalszahlen im Fokus: Ulta Beauty, Rubrik und Samsara überraschen positiv, während DocuSign und Hewlett Packard Enterprise nach den Ergebnissen unter Druck geraten. Bei SoFi sorgt eine Kapitalerhöhung für Abgabedruck vor dem Opening. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

Der Freitag liefert Tempo. Der DAX nimmt die 24.000 zurück. Zinsfantasie und starke Daten schieben den Markt an. Netflix kauft Warner Brothers für 72 Mrd. US-Dollar. Schott Pharma fällt deutlich. Stahl und Rüstung zeigen Stärke. Kupfer erreicht ein Rekordhoch. Die Interviews liefern Tiefe: Hlinka über Werte, Joeckel über Benefit Systems, Scholz über Denkfehler, Kammerer über Sanierung, Asamer über Trends und KI. Klarer Blick für das Börsenfinale.

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates. Key topics included: • The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3. • Study design and findings from the EPCOR FL1 trial. • Step-up dosing schedule and its implications for patient management. • Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). • The role of minimal residual disease (MRD) and ctDNA in treatment decisions. Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

About Ajay Gannerkote:Ajay Gannerkote is a global healthcare leader with deep experience spanning life sciences, medical devices, and healthcare services. Now serving as president of Integrated DNA Technologies (IDT), a Danaher company, he oversees the organization's growth and strategic direction from Redwood City, California. Before IDT, he led Siemens Healthineers' global ultrasound business as president and head, steering a complex, vertically integrated operation across more than 30 countries. Under his leadership, the business moved from negative growth and margins to strong, sustainable performance, becoming an industry leader in AI-driven clinical technology. Prior to that, he served as Director at KKR Capstone, where he co-led healthcare operations, drove large-scale transformations for portfolio companies, and created significant enterprise value across services and medical device sectors. Ajay spent more than a decade at McKinsey & Company as a partner in the Global Medical Products practice, advising Fortune 500 companies on product development, commercialization, operations, growth strategy, and large-scale turnarounds. Earlier in his career, he held leadership roles at Federal-Mogul, Cambridge Technology Partners, and Infosys, building a foundation in operations, technology, and global business integration. He holds an MBA in Corporate Strategy and Marketing from the University of Michigan's Ross School of Business and a bachelor's degree in Electronics and Telecommunications Engineering from the University of Mysore.Things You'll Learn:Genomic technologies, such as NGS and MRD, are enabling earlier cancer detection, sometimes years ahead of traditional diagnostic methods. This early visibility allows clinicians to intervene sooner and build more personalized treatment strategies.Precision medicine is rapidly maturing as high-quality genomic data becomes central to diagnosis, monitoring, and therapy planning. The next era of oncology will rely heavily on personalized, data-driven decisions.Collaboration across industry, researchers, and regulatory bodies is essential for breakthrough medical innovations. A recent case of a rare disease demonstrates how a coordinated effort can compress the journey from diagnosis to therapy into just a few months.Custom manufacturing and high-quality reagents are critical enablers of clinically reliable genomic insights. Tailored solutions allow researchers and clinicians to analyze tumor-specific markers with greater accuracy and confidence.Strong leadership in genomics requires trust, transparency, and a willingness to challenge assumptions. Ajay's “obligation to dissent” principle encourages continuous innovation and pushes teams to think beyond the status quo.Resources:Connect with and follow Ajay Gannerkote on LinkedIn.Follow Integrated DNA Technologies on LinkedIn and visit their website.

In today's episode, we had the pleasure of speaking with Sarah Rutherford, MD, about the evolving role of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing for lymphoma treatment decision-making. Dr Rutherford is an associate professor of clinical medicine in the Division of Hematology/Oncology at Weill Cornell Medicine in New York, New York.  In our exclusive interview, Dr Rutherford discussed the usefulness of ctDNA for guiding patient treatment, clinical trials that are ongoing to determine the best use of this type of assay, how personalized ctDNA testing offers the potential for disease surveillance and effective intervention, key hurdles in the way of widespread implementation of ctDNA testing in clinical practice, and how integration with next-generation sequencing is expected to further tailor treatment strategies.

Advances in molecular diagnostics are reshaping how cancer is detected, monitored, and treated, and liquid biopsy is becoming central to that progress. This simple blood draw can reveal key tumor biology at diagnosis and over time, providing timely insight and guiding more precise decisions throughout a patient's journey. Clinicians now face an important challenge: knowing what is actionable today and what is coming next so more patients can benefit from the promise of these advances.As we kick off Season 7, host and patient advocate Karan Cushman expands this season's focus on Bringing Precision Medicine to Everyone with a deeper look inside the science of liquid biopsy. The conversation features two leaders shaping the field: Dr. Christian Rolfo, Division Director of Medical Oncology at The James Comprehensive Cancer Center at Ohio State University, and Dr. Roberto Borea, Medical Oncologist and emerging investigator from the Rolfo Lab.Together, they break down the scientific momentum driving liquid biopsy forward, including tumor fraction, MRD-guided treatment strategies, resistance monitoring, fragmentomics, and the expanding frontier of early detection. They also discuss the barriers that continue to slow broader adoption, such as assay variability, limited standardization, reimbursement gaps, and operational challenges in community settings.In this episode, we cover:• How tumor fraction is emerging as a meaningful real-time biomarker• Where MRD-driven escalation and de-escalation strategies are heading• The current promise and limitations of early detection and MCED testing• What is required to standardize liquid biopsy across reporting, workflows, and clinical trialsEpisode 70 offers a clear look at the advances researchers are helping drive right now and what these developments could mean for clinicians, laboratories, and patients in the near future.This conversation builds on episode 69 with Dr. Kashyap Patel, who introduced the foundations of liquid biopsy and its role in accelerating treatment decisions. Combined, these two episodes offer clinicians and patients an overview of where the science and real-world applications stand now and where the field is headed next.

Apple trennt sich von KI-Chef John Giannandrea und holt einen Microsoft-Researcher. Amazon testet 30-Minuten-Lieferung in den USA – die Gorillas sind zurück. Instagram-Chef Adam Mosseri ordnet fünf Tage Büropflicht an. OpenAI investiert in Thrive Holdings und schickt Engineers mit – ein Kreislaufgeschäft oder clevere Strategie? Black Forest Labs wird mit $3,25 Mrd. zum wertvollsten deutschen KI-Startup. Sam Altman ruft nach Googles Gemini-Erfolg "Code Red" aus und verschiebt das geplante Werbemodell. US-Startups wechseln zunehmend zu chinesischen Open-Source-Modellen. MongoDB liefert starke Earnings. Frank Thelen crasht ein Schneemobil und fordert Dialog mit der AfD. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Intro (00:01:56) Apple feuert KI-Chef, holt Microsoft-Researcher (00:05:33) Amazon startet 30-Minuten-Lieferung in USA (00:11:04) Instagram: Fünf Tage zurück ins Büro (00:15:08) Pew Research: Social Media Nutzung in den USA (00:19:41) OpenAI investiert in Thrive Holdings (00:26:23) KI-Transformation: Warum sie oft scheitert (00:39:41) Black Forest Labs: $300M Finanzierung, $3,25B Bewertung (00:43:41) OpenAI plant Werbemodell (00:46:04) OpenAI Code Red nach Google Gemini Erfolg (00:50:23) US-Startups wechseln zu chinesischen Open-Source-Modellen (01:03:56) MongoDB Earnings (01:05:59) Frank Thelen: Schneemobil-Unfall & AfD-Dialog (01:18:03) David Sacks NYT-Profil & Interessenkonflikte (01:25:04) Richter auf US-Sanktionsliste verliert Kreditkarten (01:27:25) CryptoMixer Razzia (01:29:53) KI-Therapie-App Yara AI eingestellt Shownotes Apple KI-Chef John Giannandrea tritt zurück – macrumors.com Amazon testet 'Amazon Now' 30-Minuten-Lieferservice in Seattle und Philadelphia – geekwire.com Instagram return to office – sources.news Glöckler's OpenAI Bild LinkedIn OpenAI Thrive – nytimes.com OpenAI steigt beim eigenen Investor Thrive ein - "Kreislauf"-Deal – trendingtopics.eu Black Forrest Lab – linkedin.com Black Forrest Lab  – ft.com Leak bestätigt: OpenAI plant Werbung in ChatGPT – bleepingcomputer.com OpenAI Code Red – wsj.com Mehr von Silicon Valley baut auf kostenloser chinesischer KI auf. – nbcnews.com MongoDB-Aktie steigt um 15% nach Gewinn- und Umsatzschlag, starke Prognose – cnbc.com Pitch-Panne: Löwe beschädigt Garagentor mit Schneemobil von Tiroler Startup – brutkasten.com Frank Thelen: Dialog mit der AfD - "Familienunternehmer" rudern zurück – surplusmagazin.de David Sachs – nytimes.com Amazon und Paypal blockieren Richter in Europa – golem.de Schweizer und deutsche Behörden schließen cryptomixer.io im Rahmen von Geldwäsche-Bekämpfung – reuters.com Der Schöpfer einer KI-Therapie-App schließt sie aus Sicherheitsbedenken. – fortune.com

Der Bundeshaushalt 2026 steht – mit einem Volumen von 524,54 Mrd. Euro und einer Rekord-Neuverschuldung von 97,97 Mrd. Euro. In dieser Folge beleuchten wir, welche Schwerpunkte gesetzt wurden – etwa im Sozialetat (197,4 Mrd. Euro) und der Senkung der Umsatzsteuer in der Gastronomie (14,5 Mrd. Euro Mindereinnahmen). Außerdem: Was bedeutet das aktuelle EuGH-Urteil (C-387/21) zur Kassenproblematik für Gastronom:innen? Wann liegt keine Steuerschuld nach § 14c UStG vor – trotz zu hoch ausgewiesener Steuer? Und wie geht es weiter mit der Rente, den Krankenkassenbeiträgen, der Elektroauto-Förderung oder dem Kündigungsschutz? Diese Folge liefert fundierte Einordnungen zu rechtlichen Hintergründen, wirtschaftspolitischen Debatten und BMF-Schreiben. Nähere Informationen zum Podcast und alle bisherigen Folgen findest Du auf unserer neuen Website: https://www.steuer-podcast.de/ Schau gern mal vorbei und stell uns Deine Frage! Das Buch zum Podcast "Sei doch nicht besteuert" von Fabian Walter, kannst du jetzt unter folgendem Link bestellen: https://amzn.eu/d/26qeFBW Hier findest Du unsere Kontaktdaten, um bei steuerberaten.de Mandant zu werden oder eine einmalige Steuerfrage zu stellen: https://www.steuerberaten.de/kontakt/ Du hast Fragen oder Anmerkungen zum Podcast? Dann schreib uns gerne eine E-Mail an: podcast@steuerversum.de Neues „Sei doch nicht besteuert“-Buch, jetzt kaufen https://amzn.eu/d/hhFdFNV

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates. Key topics included: • The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3. • Study design and findings from the EPCOR FL1 trial. • Step-up dosing schedule and its implications for patient management. • Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). • The role of minimal residual disease (MRD) and ctDNA in treatment decisions. Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

Gemeinsam mit Philipp Wolf reite ich quer durch die Lebensmittel- und Getränkewelt. Wir besprechen welche Themen uns diesen Monat geprägt haben und geben unsere Meinung dazu Preis. Es erwarten euch lange Episoden mit viel Content für lange Auto- oder Bahnfahrten, die Begleitung beim Sport oder Spazieren. In unserer monatlichen Folge erfährst was die Branche bewegt: Wir sprechen über die Lebensmittelindustrie, E-Commerce, Quick Delivery, Gemeinschaftsverpflegung, Food-Start-ups, Innovationen, Digitalisierung/KI/Web3, Agrar, Investitionen/Insolvenzen/Exits aus der Branche.

Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltextContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Eine MIT-Studie zeigt großes Automatisierungspotenzial. Epic erwartet KI in allen Games und lehnt Kennzeichnungspflichten ab. Alibaba bringt erste eigene Hardware: eine KI-Brille mit Qwen-Modell. China umgeht Chip-Exportregeln, trainiert Modelle in Südostasien. Nvidia wirkt nach Googles TPU-Erfolg nervös, während HSBC massive Finanzierungsbedarfe für OpenAI prognostiziert. SBF versucht via X ein Comeback aus dem Gefängnis. Quantum Systems steigt mit neuer Finanzierung zum Milliardenunternehmen auf. Die EU will Plattformen für Online-Scams haftbar machen; Meta soll stark davon profitieren. Pip skizziert einen Verbraucherschutz-Bot als digitalen Bodyguard. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Intro & Shopify Black Friday Live Globe (00:03:23) X-Mitarbeiter mit Grok ersetzen (00:08:34) MIT-Studie: KI ersetzt 11,7% US-Arbeitskraft (00:16:23) Epic Sweeney: Keine KI-Labels für Games (00:26:23) Alibaba Smart-Brille mit Qwen AI für $537 (00:27:29) China trainiert KI-Modelle in Singapur & Malaysia (00:30:27) Nvidia unsouveräner Tweet nach Google TPU-Erfolg (00:35:09) OpenAI will 2,6B Nutzer & 220M zahlende Abos bis 2030 (00:46:04) HSBC: OpenAI braucht $207B bis 2030 für Breakeven (00:48:04) SBF startet Image-Kampagne (00:50:23) Quantum Systems €3B Bewertung für Aufklärungsdrohnen (00:52:29) EU: Social Networks haften für Online-Scams (00:56:59) Verbraucherschutz-Bot gegen Scams Shownotes Shopify Live Globe 2025 – bfcm.shopify.com Die Zwillinge, die Elon Musks Pläne unterstützen, X-Mitarbeiter durch Grok zu ersetzen – theinformation.com MIT-Studie: KI kann 11,7 % der US-Arbeitskräfte ersetzen – cnbc.com Epic's Sweeney: Plattformen sollen KI-entwickelte Spiele nicht kennzeichnen – gamesindustry.biz Alibaba veröffentlicht Quark-Smart-Brille mit Qwen AI – bloomberg.com Chinas Tech-Giganten verlagern KI-Training ins Ausland – ft.com NVIDIA übertrifft in KI-Plattformen, beliefert weiterhin Google – x.com OpenAI– theinformation.com OpenAI muss bis 2030 mindestens 207 Mrd. $ aufbringen, um Verluste fortzusetzen – ft.com SBF geht in die Offensive – wired.com Verteidigungs-Startup Quantum Systems erreicht €3 Milliarden Bewertung – bloomberg.com Social-Media-Giganten haften für Finanzbetrug unter neuem EU-Gesetz – politico.eu

In today's episode, we had the pleasure of speaking with Marc S. Raab, MD, about the post-induction outcomes and updated minimal residual disease (MRD) analyses from the phase 2 MajesTEC-5 study (NCT05695508), which is evaluating teclistamab-cqyv (Tecvayli)–based induction regimens in patients with newly diagnosed multiple myeloma. Dr Raab is a professor of medicine at Heidelberg University in Germany.

Mehr Experten-Interviews und tiefgehende Aktienanalysen findet ihr hier: oaws.de. Aktien hören ist gut. Aktien kaufen ist noch besser. Unser Partner Scalable Capital ist jetzt Bank und bietet euch dadurch jetzt noch bessere Konditionen. Mehr Infos findet ihr unter: scalable.capital/oaws. Eli Lilly = 1.000 Mrd. $, Foxconn kooperiert mit OpenAI und Alphabet, Ubisoft gibt Entwarnung bei wichtigem Tencent-Deal. Dazu gibt's Beef zwischen TSMC und Intel wegen Betriebsgeheimnissen und starke Zahlen von GAP. Fachkräftemangel und demografischer Wandel belasten die Wirtschaft. Und sie sind eine Gelegenheit für Amadeus Fire (WKN: 509310). Trotzdem ist die Aktie auf Rekordtief. Eine Chance? IBM (WKN: 851399) hat im Quanten-Bereich aktuell die Nase vorn. Das ist die Meinung von Daniel Volz von Kipu Quantum. Allerdings hat die Firma einige Challenger. D-Wave (WKN: A3DSV9), IonQ (WKN: A3C4QT) und Rigetti (WKN: A3DE3J) wollen vorbeiziehen. Diesen Podcast vom 24.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Apple intensiviert Nachfolgeplanung für CEO Tim Cook, Hardware-Chef gilt als Favorit. Peter Thiels Hedgefonds verkauft komplette Nvidia-Position und 75% Tesla, Smart Money flieht aus KI-Aktien. Klarna-Gründer warnt vor Billionen-Dollar-Investments in KI trotz eigener Investments in OpenAI, Perplexity und XAI. Warren Buffetts Berkshire Hathaway kauft erstmals signifikante Google-Position. Nimby-Movement gegen Data Center wächst. Jeff Bezos gründet Project Prometheus mit $6,2 Milliarden für industrielle KI in Chemie und Aerospace als Co-CEO. Robinhood liefert Cash nach Hause via GoPuff. Jack Dorsey reanimiert Vine. Schwarz-Gruppe investiert €11 Milliarden in Rechenzentrum im Spreewald. DeepMind WeatherNext 2 revolutioniert Wettervorhersage für Energy Trading. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Intro & Tim Cook Nachfolge (00:05:13) Apple Hardware am Ende der Geschichte? (00:06:32) Nvidia Earnings & Smart Money steigt aus (00:12:37) Warren Buffett kauft Google (00:18:18) Oracle (00:22:06) Data Center Nimby-Movement (00:29:46) Jeff Bezos gründet Projekt Prometheus (00:34:04) Mira Murati $50B Bewertung nach 8 Monaten (00:37:20) Robinhood liefert Cash nach Hause (00:42:18) Jack Dorsey reanimiert Vine (00:44:03) Schwarz Gruppe baut €11B Rechenzentrum (00:48:15) Google Weather Model für Energy Trading (00:52:42) Peak AI €21M Seed-Runde Shownotes Apple intensiviert Nachfolgeplanung für CEO Tim Cook – ft.com Peter Thiels Hedgefonds verkauft Nvidia-Anteile, reduziert Tesla-Position – cnbc.com „Klarna-Gründer hinterfragt Billionen-Ausgaben für KI“ – ft.com Berkshire Hathaway: Buffett investiert in Alphabet, reduziert Apple-Beteiligung – manager-magazin.de Oracle: Verlust bei $300 Mrd. OpenAI-Deal – ft.com Der Widerstand gegen Rechenzentren ist da – wired.com Jeff Bezos gründet A.I. Start-Up als Co-CEO – nytimes.com Muratis Thinking Machines plant Kapitalerhöhung bis zu 5 Milliarden Dollar – theinformation.com Robinhood Cash – wsj.com Jack Dorsey finanziert diVine, ein Vine-Neustart mit Videoarchiv – techcrunch.com Lidl-Mutter: Schwarz-Gruppe baut Rechenzentrum für elf Milliarden Euro – handelsblatt.com DeepMinds neuestes KI-Wettermode für Energiehändler – bloomberg.com Wechsel von idealo zu Peec AI: Gründe und Erfahrungen – linkedin.com

In this episode of The Top Line, Fierce’s Chris Hayden speaks with Foresight Diagnostics co-founders Dr. Jake Chabon and Dr. Max Diehn about how their company is delivering the next generation of minimal residual disease (MRD) detection in cancer care. Born from research at Stanford University, Foresight’s PhasED-Seq technology delivers ultra-sensitive detection—down to parts per ten million—enabling clinicians to identify microscopic traces of cancer that traditional imaging misses. The discussion explores how Foresight’s MRD platform, CLARITY, can have the ability to support more confident decision-making, from determining curative success in early-stage cancers to guiding consolidation treatment in lymphoma. Chabon and Diehn highlight the company’s biopharma collaborations, clinical trial integration, and evidence-driven approach to guideline inclusion. They also look ahead to a future where MRD testing becomes central to oncology surveillance, accelerating therapy approvals and complementing genomic and digital pathology tools to advance precision medicine.See omnystudio.com/listener for privacy information.

Die Futures waren einige Stunden vor Handelsstart stark im Plus, haben die gesamten Gewinne vor dem Start abgegeben. Seit Anfang September ging es an einem Montag im Nasdaq 100 zumeist bergauf. Wer nur an dem Tag in dem Index investiert war, blickt seit Anfang September auf eine Performance von 11%. Die Aktien von Google stehen weiterhin im Fokus. Berkshire Hathaway hat während des dritten Quartals eine rund $4 Mrd. Beteiligung aufgebaut. Bill Ackman von Pershing Square hat 6,3 Millionen Aktien in den Alphabet Class C-Aktien gehalten, und die Anteile an den Alphabet Class-A Aktien von 5,4 auf 4,8 Millionen gesenkt. Diese Woche soll Gemini 3 von Google an den Start gehen. Einige glauben, dass man damit OpenAI und Anthropic überholen wird. Dass Donald Trump die Zölle auf diverse Nahrungsmittel senken wird, könnte den Aktien der Restaurant- und Getränke-Bereich zugutekommen. Barron's nennt Starbucks, Chipotle, Cheesecake Factory und Keurig Dr. Pepper als Gewinner. Aramark ist auf den Betrieb von Cafeterias und Lebensmittel für Restaurants und im Unterhaltungsbereich etabliert. Die Aktie ist nach verfehlten Zahlen und Aussichten unter Druck. Ein Podcast - featured by Handelsblatt. +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ +++ Hinweis zur Werbeplatzierung von Meta: https://backend.ad-alliance.de/fileadmin/Transparency_Notice/Meta_DMAJ_TTPA_Transparency_Notice_-_Ad_Alliance_approved.pdf +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html Impressum: https://www.360wallstreet.de/impressum

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate und auf der hauseigenen European Investor Exchange, die genau auf Privatanleger zugeschnitten ist. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Disney enttäuscht, Cisco dankt KI und Verizon will entlassen. Pfizer verkauft BioNTech, CD&R kauft dafür offenbar Sealed Air. Siemens liefert ab, aber nicht genug. Merck überrascht. Alibaba will wie ChatGPT werden, JD wächst stark und BiliBili macht Gewinn. Oklo (WKN: A3CUTU) will kleine, schnelle Atomreaktoren bauen und hat dafür viele Absichtserklärungen von Tech-Giganten. Was Oklo bisher nicht hat, ist Umsatz. Dafür ist die Firma schon 17 Mrd. $ wert. Klingt riskant, ist riskant. Brüder machen einen Discounter groß. Klingt nach Aldi, ist aber B&M European Value Retail (WKN: A1154Z). Das ist einer der größten Discounter in Großbritannien und Frankreich und profitabler als die Konkurrenz. Doch er hat auch Schwierigkeiten. Diesen Podcast vom 14.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: scalable.capital/oaws. AMD will stärker wachsen, Infineon ist optimistisch und Foxconn verdient mehr als gedacht - der KI sei jeweils Dank. On wächst besonders stark in Asien, RWE überzeugt und Bayer spart gut. Ledger will an die Börse, Coinbase nicht kaufen und Circle enttäuscht. 70-Mrd.-$-Konzern AON (WKN: A2P2JR) verkauft nicht selbst Versicherungen, sondern vermittelt Kunden die passende Versicherung von anderen Firmen. Heißt: Risiko niedrig, Umsätze stabil. Ein Shortseller hat seit Ende 2024 gegen Strategy (WKN: 722713) gewettet. Jetzt hat er die Position geschlossen. Probleme hat der Konzern, der gerne eigene Aktien verkauft und Bitcoins kauft, trotzdem. Diesen Podcast vom 13.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Der Dax-Konzern SAP ist ein deutsches Schwergewicht: über 34 Mrd. Euro Umsatz im Jahr 2024, mehr als 100.000 Mitarbeiterinnen und Mitarbeiter weltweit, ein Software-Gigant. Wenn allerdings von den Treibern der künstlichen Intelligenz (KI) die Rede ist, dann fällt der Name SAP eher selten, ein eigenes großes Sprachmodell (LLM) hat das Unternehmen nicht entwickelt. Im Capital-Podcast verteidigt Philipp Herzig, SAP-CTO und KI-Chef im Konzern, diese Entscheidung. „Es ist natürlich bei jeder technologischen Disruption so, dass am Anfang die Aufmerksamkeit auf denen liegt, die die Grundlagenkomponenten bauen“, sagt er. „Wir haben uns von Anfang an darauf konzentriert, was die SAP stark macht, und das ist das Einbauen von Technologie in die betriebswirtschaftlichen Anwendungen.“ Herzig verweist darauf, dass KI bereits an vielen Stellen in den Anwendungen von SAP zum Einsatz kommt und den Kunden ein eigener KI-Assistent zur Verfügung steht. Aus seiner Sicht haben sich die großen Sprachmodelle zu einer Art Rohstoff entwickelt, auf dessen Grundlage erst die eigentlich erfolgversprechenden Anwendungen entwickelt werden. „Ich kann mich an Diskussionen bei uns erinnern, da kam gerade GPT-4, und alle waren in Ehrfurcht erstarrt“, sagt Herzig. „Ich habe aber schon damals gesagt: Der Algorithmus selbst wird schnell Commodity, das ist in den letzten 40 Jahren immer passiert. Die Frage ist, was ist differenzierend? Und das sind und waren Daten und der Fokus auf die Wertschöpfung im Unternehmen.“Eine Produktion von RTL+ Podcast.Host: Nils Kreimeier.Redaktion: Lucile Gagnière.Produktion: Andolin Sonnen. +++Weitere Infos zu unseren Werbepartnern finden Sie hier: https://linktr.ee/diestundenull +++60 Tage lang kostenlos Capital+ lesen - Zugriff auf alle digitalen Artikel, Inhalte aus dem Heft und das ePaper. Unter Capital.de/plus-gratis +++Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://datenschutz.ad-alliance.de/podcast.html +++ Wir verarbeiten im Zusammenhang mit dem Angebot unserer Podcasts Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html ++++++ Hinweis zur Werbeplatzierung von Meta: https://backend.ad-alliance.de/fileadmin/Transparency_Notice/Meta_DMAJ_TTPA_Transparency_Notice_-_A… +++Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

242 | Sam teilt wie sich Tiefs im Gründerleben anfühlen, Alex analysiert Elon Musks 1 Mrd. Dollar Gehaltspaket - in welcher Welt leben wir, wenn er seine Ziele erreicht? Plus Geschäftsideen!Sponsor dieser Folge ist HOLVI: Flexibles Banking für ein Business jeder Größe. Klick hier: ⁠https://www.holvi.com/de/lp/holvi-flex/?utm_source=digitaleoptimisten&utm_medium=podcast&utm_campaign=autumn_awareness_flex⁠ Finde eine Geschäftsidee, die perfekt zu dir passt: ⁠digitaleoptimisten.de/quiz⁠Kapitel:(00:00) Intro(01:48) Psychologische Tiefs als Gründer(15:23) Elon Musk Pay Package(27:32) NEO Robot: Genial oder Fail?(39:30) Shopify vs. Amazon - was machen sie mit ChatGPT(53:34) Geschäftsidee von Alex: Reverse Listing Real Estate(58:36) Geschäftsidee von Samuel: Pilgern24Shownotes: Gute Übersicht zu Elon Musks Pay Package: https://corpgov.law.harvard.edu/2025/09/29/the-trillion-dollar-man-comparing-musks-2018-pay-plan-to-his-latest-tesla-award/?utm_source=chatgpt.comNeo Robot Vorstellung: https://www.youtube.com/watch?v=uVcBa6NXAbkShopify Integration in ChatGPT: https://www.shopify.com/de/chatgptMehr Kontext:Elon Musk, eine mögliche 1.000-Milliarden-Dollar-Vergütung und die Frage, in welcher Welt wir leben, wenn er seine Tesla-Ziele wirklich erreicht – darum dreht sich der Kern dieser Unicorn-Ideas-Folge. Alex und Samuel sprechen über Musks gigantisches Pay Package, die Bedingungen dahinter (8,5 Billionen Bewertung, Robotaxis, Optimus-Roboter, Full Self Driving), die Folgen für Arbeitsplätze bei Uber, Amazon & Co. und die wachsende Machtkonzentration in den Händen eines einzelnen Unternehmers.Parallel dazu geht es um AI, Automatisierung und Deep Tech: humanoide Roboter wie Neo und Optimus, Teleoperation als Übergangstechnologie, die Trainingslogik von AI-Modellen und das Spannungsfeld zwischen Hype, echter Innovation und Sicherheitsrisiken. Samuel bringt Beispiele wie BauGPT und Deep-Tech-Startups in Europa ein, Alex nimmt Shopify vs. Amazon im Kontext von ChatGPT-Integration auseinander und erklärt, warum Plattform-Modelle unterschiedlich von AI profitieren.Stark persönlich wird es beim Thema Bootstrapping & Cashflow: Samuel spricht offen über Druck, Gehälter, Kreditlinien, ausstehende Rechnungen und die Balance zwischen Wachstum, Profitabilität und mentaler Gesundheit. Daraus entstehen zwei neue Geschäftsideen: „Reverse Listing Real Estate“ (Käuferinteresse an Häusern vorab sichtbar machen, statt klassischer Inserate) und „Pilgern24“ als moderner Rahmen für digitale Auszeiten, Pilgerwege und bewussten Disconnect für überlastete Professionals.Keywords:Elon Musk, Tesla Pay Package, Optimus Roboter, Robotaxis, AI Automatisierung, Deep Tech Europa, BauGPT, Shopify vs Amazon, ChatGPT Integration, Bootstrapping, Cashflow Management, Kreditlinie, Reverse Real Estate, Pilgern, Mental Health für Gründer, Digitale Optimisten, Unicorn Ideas Podcast.

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Novo Nordisk enttäuscht schon wieder, Siemens Healthineers auch. McDonald's, BMW und Vestas überraschen dafür positiv. Apple zahlt die nächste Mrd. an Google. Milliardär Carl Icahn kauft sich in US-Werkstattkette Monro ein und Snap kooperiert mit Perplexity. Alle Probleme können KI, Cloud und Co. nicht lösen. Den Abfluss von Wasser zum Beispiel. Dafür braucht es Rohre und Drainagen, und die hat Advanced Drainage Systems (WKN: A117FL). MetaMask ist einer der bekanntesten Krypto-Wallet-Anbieter. Jetzt plant die Muttergesellschaft Consensys offenbar einen Börsengang zu einer Milliardenbewertung. Außerdem geht's um den Krypto-Crash der letzten Tage. Diesen Podcast vom 06.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments. https://www.youtube.com/@scalable.capital/videos Novo Nordisk und Pfizer streiten, Metsera freut's. Norwegen will keine 1.000 Mrd. für Musk, Fresenius will weniger FMC, AMD und Uber haben Zahlen. Big-Short-Investor wettet gegen NVIDIA & Palantir, Telefonica halbiert Dividende und Nintendo verkauft mehr Switch 2. Spotify (WKN: A2JEGN) erhöht die Preise und hat mehr Premium-Kunden. Bald hat Spotify auch mehr Video-Podcasts bei Netflix. Schlecht für YouTube, gut für Spotify? Goldminenaktien sind wohl eine der komplexesten Assetklassen. Wie soll man bei der Analyse vorgehen und welche Kennzahlen sind wichtig? Wir klären's. Diesen Podcast vom 05.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Featuring an interview from Dr John Strickler, including the following topics: Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00) Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09) Tumor-informed MRD assays under clinical development (20:36) Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19) Case: A man in his late 50s with resected Stage IIA colon cancer (30:06) Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57) MRD as a future clinical trial endpoint for solid tumors; increasing incidence of colorectal cancer in younger people (40:24) Antibody-drug conjugates in the treatment of colorectal cancer (45:13) Perspectives on promising areas of clinical research in colorectal cancer (48:23) CME information and select publications

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Alphabet knackt 100 Mrd. $ Umsatz. Börse jubelt. Microsoft & Meta investieren mehr in Rechenzentren - findet Börse doof. NVIDIA knackt 5.000 Mrd. $. FED senkt Zinsen. Deutsche Bank mit Rekord. Caterpillar & Bloom Energy wachsen. Adidas enttäuscht. Mercedes-Benz (WKN: 710000) hatte zuletzt viele Probleme: Zölle, China, E-Mobilität. Doch gerade auf dem wichtigen chinesischen Markt wollen sich die Stuttgarter von der Konkurrenz absetzen. Andreessen Horowitz sagt: Krypto wird institutioneller. Stablecoins werden Mainstream. Wir sagen: Krypto wird politischer. Trump startet nämlich sein nächstes Krypto-Projekt. Diesen Podcast vom 30.10.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Featuring a slide presentation and related discussion from Dr John Strickler, including the following topics: Defining molecular residual disease (MRD); tumor-informed and tumor-naïve methods for assessing (0:00) GALAXY and BESPOKE CRC studies of a tumor-informed MRD assay to identify patients with localized colorectal cancer who have an increased risk of recurrence and those who are likely to benefit from adjuvant chemotherapy (6:56) Sustained circulating tumor DNA (ctDNA) clearance and disease-free survival outcomes for patients with localized colorectal cancer (13:21) DYNAMIC study of a ctDNA-guided approach to adjuvant chemotherapy for patients with Stage II colorectal cancer (16:17) ctDNA positivity and radiographic evidence of colorectal cancer (18:48) ctDNA-guided approaches to escalating or de-escalating adjuvant chemotherapy for patients with localized colorectal cancer (21:24) Predictive role of ctDNA assay results in Stage III colon cancer treated with celecoxib; low-dose aspirin for patients with Stage II to III colorectal cancer with a PI3K pathway alteration (26:02) CME information and select publications

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments. https://www.youtube.com/@scalable.capital/videos PayPal liefert gute Zahlen und wird in ChatGPT integriert. OpenAI hebt Microsoft über 4.000 Mrd. $. NVIDIA investiert in Nokia und damit mal wieder in eigenen Umsatz. Starke Zahlen von UPS, Wayfair und Nordex. Enttäuschung von SUSS Microtec. Skyworks kauft Qorvo. Sind digitale Preisschilder ein spannender Börsen-Case? Ja, denn es steckt mehr hinter dem Business als man erstmal denkt. Der Weltmarktführer für die Hard- und Software in dem Bereich heißt Vusion Group (WKN: A0JC1Z) und kommt aus Frankreich. Sony (WKN: 853687) hat seine Finanzsparte an die Börse gebracht und will noch stärker auf Entertainment setzen. Die Investoren danken es mit einer höheren Bewertung. Doch was plant Sony konkret? Diesen Podcast vom 29.10.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

MRD (minimal/measurable residual disease) testing is changing the way doctors understand and monitor blood cancers.  In this episode, we talk […] The post MRD Explained: What it Means for You and Your Care first appeared on The Bloodline with Blood Cancer United Podcast.

Featuring an interview with Dr Eunice S Wang, including the following topics: Hypomethylating agent/venetoclax combinations for the treatment of acute myeloid leukemia (AML); integration in community practice (0:00) All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed AML not eligible for intensive induction chemotherapy (9:39) Efficacy of targeted therapy options for AML; potential role of MRD (minimal residual disease) assays in monitoring treatment response (13:07) Treatment approach for patients with FLT3-mutant AML; mutation profiles and predicting response to quizartinib (20:14) Targeting the differentiation of AML tumor cells with IDH and menin inhibitors; associated differentiation syndrome (29:24) Efficacy and tolerability of the IDH inhibitors ivosidenib and olutasidenib (36:54) Key clinical data with approved and investigational menin inhibitors for AML; current and potential integration of menin inhibitors in the AML treatment algorithm (42:30) CME information and select publications

This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) Annual Meeting in Toronto, with special focus on bispecific antibodies and novel immunotherapies across the multiple myeloma disease continuum—from smoldering disease through relapsed/refractory settings. Dr. Alfred Garfall provides expert commentary on study design, efficacy, safety considerations, and clinical implications.Topics Covered1. SMOLDERING MULTIPLE MYELOMALINKER-SMM1Phase 2, open-label study of linvoseltamab monotherapy (200 mg) in patients with high-risk smoldering multiple myeloma by 20/2/20 or PETHEMA criteria, with 2-year treatment duration.Discussion Points:Appropriateness of 2-year treatment duration for precursor conditionEfficacy and MRD-negative ratesSafety considerations in asymptomatic populationPatient selection if available today2. NEWLY DIAGNOSED MULTIPLE MYELOMAMajesTEC-5Phase 2 trial evaluating three teclistamab-daratumumab-based induction regimens in 49 transplant-eligible NDMM patients, followed by auto-transplant and fixed-duration Tec-Dara maintenance.Discussion Points:Post-induction MRD-negativity rates with Tec-DR and Tec-DVRGrade 3-5 infection rates and infection-related deathsQuestionable utility of bortezomib and need for ASCT with 100% MRD-negativityHigh infection prophylaxis requirementsMagnetisMM-6Phase 1/2 dose-finding study of fixed-dose elranatamab 76 mg Q4W with Dara-Len in 37 transplant-ineligible NDMM patients (median age 75 years).Discussion Points:VGPR or better ratesSafety profile including infections and CRS/ICANSRisk of continuous therapy in elderly/frail populationLINKER-MM4Phase 1/2 study of linvoseltamab monotherapy in NDMM with both transplant-eligible and transplant-ineligible pathways, exploring three dose levels (50, 100, 200 mg).Discussion Points:Efficacy of single-agent Linvo in NDMMWhether any NDMM population could achieve long-term control with single-agent BCMA BsAbSafety profile3. RELAPSED/REFRACTORY MULTIPLE MYELOMACAMMA-1Phase 1b randomized dose-expansion study of cevostamab (FcRH5×CD3 bispecific) combined with pomalidomide-dexamethasone in BCMA-naïve patients with median 2 prior lines of therapy.Discussion Points:Efficacy and safety resultsPositioning in treatment paradigmUse before BCMA BsAbs?Sonrotoclax + Dexamethasone in t(11;14) R/R MMPhase 1/2 study of sonrotoclax (next-generation BCL2 inhibitor) plus dexamethasone as an all-oral regimen in patients with t(11;14) R/R MM (median 3 prior lines, ~75% triple-exposed).Discussion Points:Efficacy including response rate and PFSSafety profileFuture of BCL2 inhibitors in t(11;14) myeloma in the era of BsAbs and CAR TRedirecTT-1Phase 2 trial combining teclistamab + talquetamab in 90 heavily pretreated patients with R/R extraosseous extramedullary disease (84% triple-class refractory, 36% penta-refractory, 20% prior BCMA CAR T).Discussion Points:Response rate and durability in difficult-to-treat populationSafety concerns with dual bispecific combinationOff-label use considerations4. CAR T-CELL THERAPY TOXICITIESCAR T Immune-Related Adverse Events (UPenn Study - Ho et al)Large cohort study of 198 patients (125 cilta-cel, 73 ide-cel) examining all adverse events other than CRS, ICANS, IEC-HS, and IECAHT.Discussion Points:Landscape of CAR T IRAEs: incidence, types, and timingRisk factors identified for CirAEsMechanism of toxicities and role of CD4+ CAR T-cellsClinical implications: Should prophylactic corticosteroids be used? What ALC threshold? Optimal dose/duration? Prospective studies needed?

In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML). Join us as we dive into the essential aspects of CML treatment, including: •⁠  ⁠The importance of initial workup and bone marrow biopsy in diagnosing CML. •⁠  ⁠Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib. •⁠  ⁠Patient-centered decision-making and how to align treatment options with individual patient goals. •⁠  ⁠Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD). •⁠  ⁠The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities. •⁠  ⁠Insights into the role of transplant in accelerated and blast phases of CML. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights. #CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes